imiglucerase_for: profile and news

Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $239.0 million compared with $226.0 million in the ... - Webbolt Business News,

FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe ...  Apr 28, 2006
Genzyme has developed Cerezyme® (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme® (agalsidase beta) for Fabry disease; and, in ... - Yahoo! News (press release)

Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $239.0 million compared with $226.0 million in the ... - Yahoo! News (press release)

Genzyme's First-Quarter Sales Below Expectations  Apr 19, 2006
Though likely to continue growing only modestly in the future, sales of the flagship Cerezyme (imiglucerase for injection) for Type 1 Gaucher's disease hit ... - BioWorld Online (subscription),